Vazyme Biotech Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
3,002
- Stock Symbol
-
688105
- Investments
-
2
- Share Price
-
$3.16
- (As of Friday Closing)
Vazyme Biotech General Information
Description
Nanjing Vazyme Biotech Co Ltd is engaged in conducting technological research and product development focusing on functional proteins such as enzymes, antigens, and antibodies, as well as high molecular weight organic materials.
Contact Information
Website
www.vazyme.comCorporate Office
- Building C2, Hongfeng Science and Technology Park
- Kechuang Road, Nanjing Economic and Technological Development Zone
- Nanjing, Jiangsu
- China
Corporate Office
- Building C2, Hongfeng Science and Technology Park
- Kechuang Road, Nanjing Economic and Technological Development Zone
- Nanjing, Jiangsu
- China
Vazyme Biotech Stock Performance
As of 13-Nov-2026, Vazyme Biotech’s stock price is $3.16. Its current market cap is $1.63B with 517M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.16 | $3.43 | $1.91 - $4.35 | $1.63B | 517M | 13.8M |
Vazyme Biotech Financials Summary
As of 30-Sep-2026, Vazyme Biotech has a trailing 12-month revenue of $226M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,825,120 | 871,838 | 972,468 | 1,500,847 |
| Revenue | 225,837 | 191,603 | 192,029 | 181,768 |
| EBITDA | (1,721) | 16,512 | 14,400 | 3,445 |
| Net Income | 144 | (2,310) | (2,522) | (10,029) |
| Total Assets | 731,275 | 718,620 | 691,588 | 810,622 |
| Total Debt | 127,826 | 120,405 | 102,973 | 181,562 |
Vazyme Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vazyme Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Vazyme Biotech Patents
Vazyme Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026188834-A1 | Adapter oligonucleotide, linker oligonucleotide, and sequencing library construction method | Pending | 11-Mar-2025 | ||
| WO-2026157441-A1 | Method for preparing intermediate peptide of glp-1 peptide or analogue thereof | Pending | 21-Jan-2025 | ||
| WO-2026157442-A1 | Method for preparing intermediate peptide of glp-1 peptide or analogue thereof | Pending | 21-Jan-2025 | ||
| WO-2026144572-A1 | Transposase library construction method for reducing linker dimers in library | Pending | 02-Jan-2025 | ||
| JP-2026010073-A | Rna polymerase mutants and uses thereof | Pending | 14-Oct-2024 | C12N9/1247 |
Vazyme Biotech Signals
Vazyme Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vazyme Biotech Investments (2)
Vazyme Biotech’s most recent deal was a Early Stage VC with Huiliao for . The deal was made on 14-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Huiliao | 14-Jan-2025 | Early Stage VC | Pharmaceuticals | ||
| CYGENTA (China) | 25-Oct-2022 | Early Stage VC | BPO/Outsource Services |
Vazyme Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Vazyme Biotech FAQs
-
When was Vazyme Biotech founded?
Vazyme Biotech was founded in 2012.
-
Where is Vazyme Biotech headquartered?
Vazyme Biotech is headquartered in Nanjing, China.
-
What is the size of Vazyme Biotech?
Vazyme Biotech has 3,002 total employees.
-
What industry is Vazyme Biotech in?
Vazyme Biotech’s primary industry is Diagnostic Equipment.
-
Is Vazyme Biotech a private or public company?
Vazyme Biotech is a Public company.
-
What is Vazyme Biotech’s stock symbol?
The ticker symbol for Vazyme Biotech is 688105.
-
What is the current stock price of Vazyme Biotech?
As of 13-Nov-2026 the stock price of Vazyme Biotech is $3.16.
-
What is the current market cap of Vazyme Biotech?
The current market capitalization of Vazyme Biotech is $1.63B.
-
What is Vazyme Biotech’s current revenue?
The trailing twelve month revenue for Vazyme Biotech is $226M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process